{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(4)"],"submitter":["Kelly RJ"],"pubmed_abstract":["Background
This pharmacodynamic trial evaluated the effect of CBT-1® on efflux by the ATP binding cassette (ABC) multidrug transporter P-glycoprotein (Pgp/MDR1/ABCB1) in normal human cells and tissues. CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically. Laboratory studies showed potent and durable inhibition of Pgp, and in phase I studies CBT-1® did not alter the pharmacokinetics of paclitaxel or doxorubicin.Methods
CBT-1® was dosed at 500 mg/m2 for 7 days; a 3-hour infusion of paclitaxel at 135 mg/m2 was administered on day 6. Peripheral blood mononuclear cells (PBMCs) were obtained prior to CBT-1® administration and on day 6 prior to the paclitaxel infusion. (99m)Tc-sestamibi imaging was performed on the same schedule. The area"],"journal":["The oncologist"],"pagination":["512"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3336838"],"repository":["biostudies-literature"],"pubmed_title":["A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors."],"pmcid":["PMC3336838"],"pubmed_authors":["Oldham RK","Caluag Z","Fojo T","Draper D","Robey RW","Chen CC","Barnett D","Kelly RJ","Luchenko V","Frye AR","Steinberg SM","Bates SE"],"additional_accession":[]},"is_claimable":false,"name":"A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.","description":"Background
This pharmacodynamic trial evaluated the effect of CBT-1® on efflux by the ATP binding cassette (ABC) multidrug transporter P-glycoprotein (Pgp/MDR1/ABCB1) in normal human cells and tissues. CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically. Laboratory studies showed potent and durable inhibition of Pgp, and in phase I studies CBT-1® did not alter the pharmacokinetics of paclitaxel or doxorubicin.Methods
CBT-1® was dosed at 500 mg/m2 for 7 days; a 3-hour infusion of paclitaxel at 135 mg/m2 was administered on day 6. Peripheral blood mononuclear cells (PBMCs) were obtained prior to CBT-1® administration and on day 6 prior to the paclitaxel infusion. (99m)Tc-sestamibi imaging was performed on the same schedule. The area","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012","modification":"2025-04-04T08:48:27.205Z","creation":"2019-03-27T00:52:40Z"},"accession":"S-EPMC3336838","cross_references":{"pubmed":["22416063"],"doi":["10.1634/theoncologist.2012-0080"]}}